China's semaglutide generics remain stuck behind data exclusivity

Semaglutide's core compound patent has expired in China, but as of late April 2026 no domestic generic version had received marketing approval there, according to a report describing more than a month of delay with no movement ^[1]. Chinese drugmakers say the holdup is not a rejection but a suspension tied to data exclusivity provisions in the China-Switzerland free trade agreement, which can protect the original clinical trial data used to win approval even after the underlying patent lapses ^[1].

Three companies described their applications as frozen in place. Hangzhou Jiuyuan Gene Engineering said the reason for the missing approval certificate is that "the relevant data is still under protection," adding that the process is "simply in a suspended state" rather than approved or denied ^[1]. Livzon Pharmaceutical Group said its application had reached "the final stage" of review before stalling, and attributed the freeze specifically to the FTA's terms ^[1]. The United Laboratories said it is "also waiting for the approval certificate," calling the delay "the same for everyone," which suggests an industry-wide regulatory pause rather than a problem with any single company's paperwork ^[1].

One of the furthest-along programs belongs to Jiuyuan Genetic Biopharmaceutical. China's National Medical Products Administration accepted for review the company's marketing application for Jikeqin, a generic version referencing semaglutide's weight-management brand, on February 25, 2026 ^[2]. A Phase 3 trial for Jikeqin, approved in China in January 2024, has since been completed and the results submitted to the Center for Drug Evaluation ^[2].

Outside China, generic semaglutide is moving at different speeds depending on the country's patent and exclusivity rules. In India, Sun Pharmaceutical, Zydus Lifesciences, and Alkem Laboratories received regulatory approval to manufacture and sell generic versions in January 2026, with Zydus saying it plans to launch injections under the brand names Semaglyn, Mashema, and Alterme once the patent lifts, and a separate report saying Dr. Reddy's is aiming for a price as much as 60% below the original in India ^[2]. Dr. Reddy's has also said it intends to launch its generic in 87 countries during 2026, starting with Canada, India, Brazil, and Turkey ^[2]. In Canada, the patent has already expired and regulatory exclusivity lapsed in January 2026, with Health Canada reviewing nine generic submissions from companies including Sandoz, Apotex, Teva, Aspen Pharmacare, and Taro Pharmaceuticals ^[2].

Why it matters for patients

This dispute is unfolding in China and does not change access, coverage, or pricing for semaglutide products sold in the United States as Ozempic, Wegovy, or Rybelsus. But it illustrates a pattern that also matters for American patients tracking when lower-cost competition might arrive anywhere: a patent expiring is not the same as a generic being allowed on the market. Separate data exclusivity rules, often set through trade agreements, can keep a brand-name drug's competitive position intact even after its patent runs out ^[1]. One report framed the China delay as extending the window in which the original manufacturer, Novo Nordisk, keeps pricing power in that market longer than the patent timeline alone would suggest ^[1]. For now, the international generic landscape remains uneven, with India and Canada further along than China ^[2].

What happens next

Chinese regulators are expected to approve domestic semaglutide generics once they determine the data exclusivity period required under the FTA has fully run out, but no date for that determination has been reported ^[1]. Until then, applications from Hangzhou Jiuyuan Gene Engineering, Livzon Pharmaceutical Group, and The United Laboratories remain in suspension, and Jiuyuan's Jikeqin application continues under review following its February 2026 acceptance ^{[1] [2]}.